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This chapter introduces pharmacovigilance in the European Union (EU); due to the 
multi-level nature of the EU, pharmacovigilance is described both at the European 
and the national level . Both levels are linked through multiple inter-institutional 
relations and, in combination, the European and national levels make up the EU’s 
pharmacovigilance system . 
A simplified visual representation of the system is shown in Fig . 3 .1, illustrating 
the main connections of the most important players of the system discussed in this 
chapter . Depending on the regulatory procedure and the life cycle of the medicine, 
these actors are connected in varying networks .
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In the past, EU pharmaceuticals regulation only included the efficient authorisation 
of medicinal products . The regulation continues to serves a dual objective, namely 
the free movement of medicinal products in the EU and the protection of public 
health . Marketing authorisation can be obtained through a decentralised procedure 
by Member States or in a centralised procedure by the European Medicines Agency 
(EMA) .3 During the course of these procedures, medicinal products undergo risk 
assessment to test their quality, safety and efficacy . Thus, the assessment of risks 
and benefits before marketing is the cornerstone of authorisation .
Hence, the emphasis was traditionally put on the risk assessment before mar-
keting, and the continuous assessment of authorised products used to be neglected 
(see Abraham and Lewis 2000) . In the 1990s, this began to change when the EU 
passed a series of legislations dedicated to pharmacovigilance . Today, EU regu-
lation covers the whole life cycle of medicinal products: drug development and 
manufacturing, clinical trials, marketing authorisation and pharmacovigilance 
(see Scholz 2015) . This includes not only the spontaneous reporting of adverse drug 
reactions (ADRs), but also systematic reporting through risk management plans 
(Moore and Begaud 2010) .
In this chapter, we give an overview of the pharmacovigilance system in the EU . 
First, we introduce the main legislative and executive institutions in the EU, namely 
the European Commission (Commission), the Council of Ministers (Council) and 
the European Parliament (EP) as well as the actors responsible for implementing 
pharmacovigilance policy . We then give a brief overview of pharmacovigilance 
legislative developments, notably Directive 2001/83/EC and the subsequent reform 
through Directive 2010/84/EU and conclude by presenting the most important 
changes brought about by the reform Directive and discussing the ADR provisions 
in the Directive .
3 Pharmaceuticals authorised through the centralised procedure can be marketed through-
out the entire EU . For some medicinal products, such as those derived from biotechnology 
processes, the centralised procedure is mandatory . For medicinal products outside of the 
scope of the centralised procedure, pharmaceutical companies can opt for decentralised 
procedures, whereby these products can then only be marketed in a few Member States .
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3.1 EU Institutions and Pharmacovigilance Actors
For a better understanding of the EU system of pharmacovigilance, it is important 
to distinguish between two sets of actors . The first set of actors comprises the EU 
institutions which pass pharmaceutical regulations and set the policy framework for 
pharmacovigilance . The Commission, the Council and the EP are the institutions 
with legislative and executive tasks in the EU . Together, they can be conceived of 
as a legislative triangle .
The European Commission performs a variety of functions and is the institution 
which is supposed to represent European interests . Varying policy issues are dealt 
with by so-called Directorate Generals (DGs); DG Health and Food Safety (SANTE) 
handles the pharmaceuticals regulation . DG SANTE is also the “parent” DG of EMA, 
which means that representatives of this DG are important points of reference for 
the day-to-day activities of the agency . However, representatives of both DGs are 
members of the EMA Management Board which is the main steering body of the 
agency . Among its many functions, the initiation of legislation is a key task of the 
Commission . In addition, EU legislation can only be adopted based on proposals by 
the Commission . Regarding its executive functions, the Commission is supported 
by an expert group, the Pharmaceutical Committee, which was established in 1975; 
this committee consists of representatives of the Member States and EMA . Its main 
tasks relate to the implementation of pharmaceuticals legislation and particularly 
Directive 2001/83/EC, and it is supervised by DG SANTE .
The Council of Ministers has primarily legislative functions and is the institution 
which represents the Member States . Depending on the policy subject at stake, the 
Council convenes and negotiates in varying configurations with different national 
ministers present at meetings . Regarding the revision of Directive 2001/83/EC, the 
Council convened in two different configurations: the Employment, Social Policy, 
Health and Consumer Affairs (EPSCO) group as well as Agriculture and Fisheries 
(AGRIFISH) . Together with the EP, the Council passes legislative acts such as the 
aforementioned pharmacovigilance legislation .
The European Parliament (EP) representing the people of Europe is, together 
with the Council, the legislature of the EU . Legislative proposals initiated by the 
Commission are dealt with by one or more parliamentary committees . Directive 
2001/83/EC, for instance, was handled by the Environment, Public Health and Food 
Safety (ENVI) committee with two other committees providing further opinions 
on the legislative proposal .4 The EP is entitled to send two representatives to the 
4 Internal Market and Consumer Protection (IMCO) and Industry, Research and Energy 
(ITRE) .
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EMA Management Board . Usually, scientific experts are sent to represent the EP . 
As part of the legislature, the EP also plays an important role regarding budgetary 
oversight and control of EMA . However, the EP plays a limited role regarding the 
practical implementation of pharmacovigilance policies .
The second set of actors is responsible for implementing pharmacovigilance 
policy at the EU and national levels, based on the legislation passed by the EU in-
stitutions . As will be explained in Chapter 4, national legislatures have to transpose 
EU directives into national law . In addition, implementing legislation is adopted by 
the EU at the EU level . Yet this set also comprises the EMA, the national competent 
authorities, and pharmaceutical companies and other stakeholders .
The main task of the European Medicines Agency (EMA) is to coordinate the 
evaluation of medicinal products and to advise the EU institutions and the Member 
States on any issue relating to pharmaceuticals regulation . Since it began operating 
in 1995, the agency has become a central actor regarding various aspects of phar-
maceuticals regulation and has a crucial role in providing the infrastructure for EU 
pharmacovigilance . For its scientific assessments, the agency relies on a number 
of committees, including the Committee for Medicinal Products for Human Use 
(CMPH), which issues recommendations to the Commission regarding the cen-
tralised authorisation procedure . In addition, since 2012, the Pharmacovigilance 
Risk Assessment Committee (PRAC) assesses and monitors the safety of medici-
nal products . PRAC issues opinions and recommendations about centralised and 
decentralised authorisation procedures .
The EMA’s EudraVigilance database is an internet-based information system 
where reports of suspected adverse reactions are collected . It is legally required 
that ADRs occurring in the EU must be included in the database by the Member 
States and marketing authorisation holders .
Furthermore, the pharmacovigilance system of the EU relies heavily on the 
Member States and their national competent authorities . As can be seen in Fig . 
3 .1, Member State actors are involved in almost all pharmacovigilance activities . 
Drawing on national expertise and resources, the national competent authorities 
are at the centre of pharmacovigilance implementation and enforcement activities 
(see European Commission 2016a) . These authorities are not only at the centre of 
practical implementation at the national level, but also represented at the EU level 
in the various EMA committees dealing with authorisation and pharmacovigilance .
At the EU level, the Co-ordination Group for Mutual Recognition and De-
centralised Procedures (CMDh) is in charge of decision-making when medic-
inal products are marketed through the decentralised procedure . In addition, 
the Strengthening Collaboration for Operating Pharmacovigilance in Europe 
(SCOPE) Joint Action initiative supports the operation of EU pharmacovigilance 
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by delivering training, tools and templates to support best practices (European 
Commission 2015) . The European Network of Centres for Pharmacoepidemiology 
and Pharmacovigilance (ENCePP) also aims to improve the science and practice 
of pharmacovigilance .
At the national level, the national competent authorities are the central bodies 
supervising the collection of information about suspected ADRs submitted by 
healthcare professionals, marketing authorisation holders and patients . By doing 
so, these authorities provide for resources, knowledge and expertise regarding 
causality assessment and signal detection (European Commission 2016b) .
Pharmacovigilance is based on the EMA’s close connections with the pharma-
ceutical industry (see Wiktorwowicz et al . 2012) and include risk management 
plans and post-authorisation safety studies which are important elements of the 
authorisation procedure and product surveillance after marketing . Regarding 
pharmacovigilance, marketing authorisation holders have to comply with a number 
of stipulations laid down in EU legislation . For instance, they have to appoint a 
responsible person in charge of pharmacovigilance who serves as the main contact 
point for regulatory authorities . In addition, marketing authorisation holders are 
also legally obligated to report ADRs .
Finally, some additional stakeholders are significant in the proper implemen-
tation of the EU pharmacovigilance legislation .
Regulation (EC) No 726/2004 explicitly mentions the participation of stake-
holders in EU pharmaceuticals regulation . In the framework of EMA, a network of 
European patient and consumer organisations as well as a Patients’ and Consumers’ 
Working Party have been established .
The reform of the pharmacovigilance system by Directive 2010/84/EU has 
introduced the possibility for patients to report suspected side effects directly, ei-
ther to the national competent authorities or the marketing authorisation holders . 
As explained below, the Directive also aims to simplify and facilitate individual 
reporting by patients .
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Although pharmaceuticals regulation in the EU dates back to the 1960s, pharma-
covigilance was neglected until the 1990s, when the EU began to pass a series of 
legislations dedicated to pharmacovigilance (see Abraham and Lewis 2000) . Already, 
Directive 93/39/EEC stated that Member States must establish pharmacovigilance 
systems and encourage healthcare professionals to report ADRs . Marketing au-
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thorisation holders were also requested to appoint a qualified person responsible 
for pharmacovigilance .
At that time, EU pharmaceuticals regulation consisted of various pieces of legisla-
tion that were interconnected in complex ways . Hence, with a view to simplification, 
the various pieces were codified in a single text, leading to Directive 2001/83/EC . 
This Directive is the legal basis of the EU legislation on pharmacovigilance and has 
been amended 10 times . Compared with Directive 93/39/EEC, the requirements 
for Member States and marketing authorisation holders to set up and maintain 
pharmacovigilance systems did not change substantially . Hence, the relevant pro-
visions, introduced in essence in the early 1990s, were merely consolidated in Title 
IX of Directive 2001/83/EC which was dedicated to pharmacovigilance .
In 2006, the Commission initiated a public consultation with a view to reform 
the pharmacovigilance system . The goals stated by the Commission included clari-
fying stakeholder responsibility, ensuring the involvement of varying stakeholders 
(including healthcare professionals and stakeholders), and clarifying duplications 
and responsibilities . The public consultation was accompanied by an assessment 
report, which found “disparities and inconsistencies resulting from a non-optimal 
compliance of both national law and practice with the EC regulations” (European 
Commission 2006) .
Based on the consultation, the Commission issued a legislative proposal in 
December 2008 . In this proposal, the Commission explained that it was aiming at 
the following objectives: better protection of public health, proper internal market 
functioning, and a simplification of the current rules and procedures (European 
Commission 2008) .
The proposal was then discussed by the Member States in the respective Council 
working group throughout the next year . After beginning preparatory talks in late 
2009, the Council and the EP engaged in a series of informal meetings (so-called 
trialogues) with a view to ensuring the quick adoption of the Directive (Council of 
the European Union 2010) . In September 2010, the EP passed Directive 2010/84/
EU with a majority, thus concluding the legislative procedure .
Additional legislation is important to maintain the EU pharmacovigilance system . 
While Directive 2010/84/EU covers pharmacovigilance regarding decentralised 
authorisation, Regulation (EU) No 1235/2010 covers the centralised authorisa-
tion procedure . Operational aspects for these legislations were adopted through 
Commission Implementing Regulation No 520/2012 . For instance, the regulation 
stipulates that individual case safety reports concerning biologicals must contain 
the batch numbers . Furthermore, Implementing Regulation No 198/2013 introduces 
the “black triangle” (▼) . The recital of the Regulation is as follows:
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Some medicinal products for human use are subject to additional monitoring 
because of their specific safety profile, including medicinal products with a new 
active substance, biological medicinal products and products for which post-au-
thorisation data are required (see also James 2014) . As the Commission explains 
on its website, the black triangle (▼) aims to highlight to patients the importance 
of reporting suspected side effects stemming from the medicines they are taking, 
improving their safety .
A product which is subject to additional monitoring is included in an online up-
to-date list which is publicly available on the EMA homepage . All products on this 
list must display an inverted black triangle symbol (▼) and include a standardised 
explanatory sentence in both their summary of product characteristics and in the 
package leaflet (European Commission 2014: 15) . This additional list was launched 
by the EMA in April 2013 and draws attention to and increases transparency for 
patients in order to encourage the reporting of suspected adverse effects .
Finally, Regulation (EU) No 1027/2012 and Directive 2012/26/EU amended 
the legislation due to the withdrawal of a medicine called Mediator (benfluorex) 
(cf . Box 5 .4 in Chapter 5 .4) . These amendments require a marketing authorisation 
holder to notify the competent authority of that Member State when a medicine is 
withdrawn from the market .
Complementing legislation, the EU system of pharmacovigilance comprises 
a set of technical principles described in respective guidance documents . These 
principles ensure that the requirements of pharmaceuticals regulation are applied 
in a uniform manner . These principles include good manufacturing practice (GMP), 
good distribution practice (GDP) and good pharmacovigilance practice (GVP) . The 
GVP guidance documents aim to facilitate pharmacovigilance in the EU and cover 
medicines authorised through both the centralised and the decentralised procedure .
3.3 The Pharmacovigilance Reform: Directive 2010/84/EU 
and Article 102
3.3 The Pharmacovigilance Reform
The aim of the new pharmacovigilance Directive 2010/84/EU is “to improve the 
operation of Union law on the pharmacovigilance of medicinal products” (Recital 
3) . In summary, the new legislation brought about the following changes to the EU 
system of pharmacovigilance:
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•	 Extension of the scope for additional monitoring (e .g . of biologicals)
•	 Competent authorities may require additional monitoring for products that are 
subject to studies after marketing
•	 Medicinal products subject to additional monitoring are required to be identified 
by the black triangle (▼) and to be included in a publicly available list
•	 Patients are encouraged to report ADRs directly to the competent authorities
•	 ADRs are extended to include medication errors and overdose
The reform of the EU pharmacovigilance system aimed at facilitating ADR reporting 
with a specific emphasis on the identification of biologicals (European Commission 
2007) . To this end, the Commission enhanced Articles 101 and 102 which laid 
down provisions in this respect (Box 3 .1) . In these articles, three elements can be 
identified: 1) Member States must take measures to encourage healthcare profes-
sionals to report ADRs; 2) Member States may impose specific requirements to do 
so; 3) Member States must establish a pharmacovigilance system . The revision of 
these provisions through Directive 2010/84/EU mainly extends the latter element, 
whereas the former two elements were retained as described .
The extension of these provisions proved to be a controversial subject with 
Member States . Based on the initial provision of the Commission proposal, Arti-
cle 102 alone sparked 14 comments, with nine Member States requesting changes 
(Council of European Union 2009) . Throughout the legislative procedure, the exact 
wording of these provisions was subject to much discussion among Member States .
In total, the parliamentary committees dealing with the Commission proposal 
tabled more than 70 amendments . Throughout the informal trialogue meetings with 
the Council, a compromise text was developed which did not retain all amendments 
in the proposed wording, but which maintained key stipulations included by the EP .
Pharmacovigilance provisions in Article 102 of Directive 2010/84/EU were 
adopted as follows (Box 3 .1):
The Member States shall:
a . take all appropriate measures to encourage patients, doctors, pharmacists and 
other healthcare professionals to report suspected adverse reactions to the 
national competent authority; for these tasks, organisations representing con-
sumers, patients and healthcare professionals may be involved as appropriate;
In the Commission proposal and in the Council discussions, patients were not orig-
inally included . The inclusion of patients in this stipulation is due to the amendment 
of the EP which was eventually retained in the compromise text; in the literature, 
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there is no agreement on whether patients’ inclusion improves pharmacovigilance 
by extending the scope of actors reporting ADRs or whether such inclusion leads 
to information overload and a diminution of the quality of the reports (see e .g . de 
Langen et al . 2008) . The inclusion of consumer and patients’ organisations is also 
due to the parliamentary amendment; their role, however, was diminished in the 
compromise text .
b .  facilitate patient reporting through the provision of alternative reporting formats 
in addition to web-based formats;
In connection with the general inclusion of patients in ADR reporting in point a), 
this stipulation was also included due to parliamentary amendment .
c . take all appropriate measures to obtain accurate and verifiable data for the 
scientific evaluation of suspected adverse reaction reports;
d . ensure that the public is given important information on pharmacovigilance 
concerns relating to the use of a medicinal product in a timely manner through 
publication on the web portal and through other means of publicly available 
information as necessary;
The wording of point c) was subject to much discussion among Member States . 
In contrast to the original stipulation of the Commission proposal, the Council 
added the provision relating pharmacovigilance to scientific evaluation . This was 
absent in the proposal which only spoke of “high quality information” . A parlia-
mentary amendment extending this “quality” stipulation to not only reports but 
also databases was not included in the compromise text . However, the stipulation 
on risk communication due to ADR reporting in point d) was included by the EP 
and retained in the final text .
e .  ensure, through the methods for collecting information and where necessary 
through the follow-up of suspected adverse reaction reports, that all appropriate 
measures are taken to identify clearly any biological medicinal product pre-
scribed, dispensed, or sold in their territory which is the subject of a suspected 
adverse reaction report, with due regard to the name of the medicinal product, 
in accordance with Article 1(20), and the batch number;
Based on the Commission proposal, the exact wording regarding the identification 
of biologicals was also the subject of much discussion among the Member States . 
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However, a substantial amendment was made by the EP . First, the EP extended the 
scope of the stipulation to suspected adverse reaction reports . Second, in contrast 
to the original stipulation, the EP explicitly included the name of the medicinal 
product, the international non-proprietary name, the name of the marketing au-
thorisation holder and the batch number . The members of the respective committee 
justified the amendment with the concern that the Commission proposal lacked 
details on how to identify biologicals . According to this view, a lack of details would 
lead to different national pharmacovigilance approaches for medicinal products 
subject to centralised authorisation . In the compromise text, the elements of re-
porting, including the batch number, were maintained . In addition, the wording 
of the stipulation was softened and the references to EudraVigilance and standard 
reporting formats were deleted .
f . take the necessary measures to ensure that a marketing authorisation holder who 
fails to discharge the obligations laid down in this Title is subject to effective, 
proportionate and dissuasive penalties .
For the purposes of point (a) and (e) of the first paragraph the Member States 
may impose specific obligations on doctors, pharmacists and other healthcare 
professionals .
In the original stipulation of the Commission proposal and the various versions of 
the Council discussions, the imposition of specific obligations were only foreseen 
for point (a), hence the general reporting requirements . In its amendment, the EP 
extended the possibility of imposing obligations to point (e), hence the reporting 
details regarding biologicals . The Commission also included the following stipulation: 
“Reporting of suspected adverse reactions due to medication errors should be on 
a ‘no blame’ basis, and should be legally privileged” (European Parliament 2010) .5
Relating to the justification regarding the specific elements of reporting in point 
(e), the EP reasoned that this amendment would not only increase the clarity of 
the provision, but would also strengthen the legal basis for requesting from health 
professionals requirements regarding the identification of biologicals . While the 
extension of specific obligations to point (e) was retained, the latter amendment 
was not included in the compromise text .
5 During the parliamentary committee discussions, an additional amendment was pro-
posed whereupon medication errors could have been reported anonymously . However, 
this amendment was not included by the responsible rapporteur in the EP report on 
amendments .
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